

Table 1. Clinicopathological information of patients

Variables	<i>DPYD</i> expression in patients treated with gemcitabine			<i>DPYD</i> expression in patients treated without gemcitabine		
	High (n = 42)	Low (n = 42)	P-value	High (n = 27)	Low (n = 27)	P-value
Median age, years (interquartile range)	66 (57–72)	61.8 (57–73)	0.71	57 (50–66)	56 (53–61)	0.80
Gender, n(%)						
Male	28 (66.7%)	34 (81.0%)	0.21	19 (70.3%)	20 (74.1%)	0.76
Female	14 (33.3%)	8 (19.0%)		8 (29.7%)	7 (25.9%)	
Clinical T-stage, n(%)						
cT2	17 (40.5%)	24 (57.1%)	0.34	5 (18.5%)	11 (40.7%)	0.11
cT3	17 (40.5%)	13 (30.9%)		16 (59.3%)	9 (33.3%)	
cT4	8 (19.0%)	5 (11.9%)		6 (22.2%)	7 (25.9%)	
Pathological T-stage, n(%)						
pT0	14 (33.3%)	20 (47.6%)	0.04*	12 (44.4%)	11 (40.7%)	0.38
pT1	3 (7.1%)	2 (4.8%)		2 (7.4%)	2 (7.4%)	
pT2	6 (14.3%)	11 (26.2%)		1 (3.7%)	7 (25.9%)	
pT3	14 (33.3%)	5 (11.9%)		4 (14.8%)	5 (18.5%)	
pT4	5 (11.9%)	4 (9.5%)		6 (22.2%)	2 (7.4%)	
NA	0 (0%)	0 (0%)		2 (7.4%)	0 (0%)	
Pathological N-stage, n(%)						
pN0	33 (78.6%)	31 (73.8%)	0.26	17 (63.0%)	12 (44.4%)	1.00
pN1–3	5 (11.9%)	10 (23.8%)		0 (0%)	0 (0%)	
NA	4 (9.5%)	1 (2.4%)		10 (37.0%)	15 (55.6%)	
NAC regimen, n(%)						
GC	37 (88.1%)	36 (85.7%)	0.75	0 (0%)	0 (0%)	1.00
GCarbo	5 (11.9%)	6 (14.3%)		0 (0%)	0 (0%)	
MVAC	0 (0%)	0 (0%)		27 (100%)	27 (100%)	
Recurrence, n(%)						
Absence	26 (61.9%)	30 (71.4%)	0.49	17 (63.0%)	16 (59.3%)	0.57
Presence	16 (38.1%)	12 (28.6%)		8 (29.6%)	11 (40.7%)	
NA	0 (0%)	0 (0%)		2 (7.4%)	0 (0%)	
Survival, n(%)						
Alive	26 (61.9%)	35 (83.3%)	0.049*	20 (74.1%)	18 (66.7%)	0.77
Death	16 (38.1%)	7 (16.7%)		7 (25.9%)	9 (33.3%)	

*Statistically significant.

NA, not available; NAC, neoadjuvant chemotherapy; GC, gemcitabine/cisplatin; Gcarbo, gemcitabine/carboplatin; MVAC, methotrexate/vinblastine/doxorubicin/cisplatin